<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994174</url>
  </required_header>
  <id_info>
    <org_study_id>583-13-FB</org_study_id>
    <nct_id>NCT01994174</nct_id>
  </id_info>
  <brief_title>Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics</brief_title>
  <official_title>Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab,&#xD;
      ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular&#xD;
      disease. The underlying hypothesis is that anti-VEGF drugs increase intraocular pressure&#xD;
      (IOP) by increasing aqueous inflow, decreasing uveoscleral outflow or both. The specific aim&#xD;
      is to evaluate the changes produced in AHD after 1 baseline and a subsequent 1 monthly&#xD;
      injection of anti VEGF agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal injection of different anti-VEGF agents such as bevacizumab (Avastin, Genentech,&#xD;
      Inc., South San Francisco, CA, USA) ranibizumab (Lucentis; Genentech, Inc., South San&#xD;
      Francisco, CA, USA) and aflibercept (Eylea, Regeneron, Tarrytown, NY, USA) has been a widely&#xD;
      common practice for treatment of choroidal neovascularization and retinal vascular diseases&#xD;
      [1]. Several ocular and systemic adverse events have been reported with the use of anti-VEGF&#xD;
      agents [7]. Elevation of intraocular pressure (IOP) is a serious ocular adverse event that&#xD;
      may be associated with intravitreal injection of anti-VEGF agents. IOP elevation with&#xD;
      anti-VEGF injection may have variable presentation ranging from acute transient post&#xD;
      injection elevation to the development of persistent IOP elevation that mandates pressure&#xD;
      lowering therapy[8].&#xD;
&#xD;
      Patients with previously existing glaucoma may have a higher rate of persistent IOP elevation&#xD;
      associated with intravitreal injection of anti-VEGF agents. Good et al, reported the rate of&#xD;
      persistent IOP elevation after intravitreal anti-VEGF to be 33% in glaucoma patients versus&#xD;
      3.1% in eyes without previous diagnosis of glaucoma [9]. Tseng et al, reported 25 eyes with&#xD;
      sustained elevation of IOP after serial intravitreal injections of anti-VEGF agents (mean =&#xD;
      20injections). All the 25 eyes were normotensive prior to the study and 23 of them were not&#xD;
      previously diagnosed with glaucoma[10].&#xD;
&#xD;
      Multicenter clinical trials that studied the intravitreal injection of anti-VEGF agents, such&#xD;
      as MARINA and ANCHOR for ranibizumab, VISION for pegaptanib and PACORES for bevacizumab, did&#xD;
      not show sustained IOP elevation with the intravitreal injection of the study agents [12-15].&#xD;
      However, a subgroup analysis of the data of MARINA and ANCHOR trials showed at least 6 mm Hg&#xD;
      increase of IOP from baseline in 2.1% of eyes in MARINA trial and 3.6% of eyes in ANCHOR&#xD;
      trial [16]. A retrospective chart review of 207 patients over a 6-months follow up period&#xD;
      after serial intravitreal injections of anti-VEGF reported an IOP elevation greater than 5 mm&#xD;
      Hg in 2 consecutive visits compared to baseline in 11.6% of the treated eyes versus 5.3% in&#xD;
      control eyes [17].&#xD;
&#xD;
      The pathophysiology of the reported IOP elevation associated with intravitreal injection of&#xD;
      anti-VEGF is unknown. Anti-VEGF compounds might increase aqueous humor inflow by the&#xD;
      breakdown of the blood-aqueous barrier or reduce uveoscleral outflow by the ciliary body&#xD;
      vasculature. These potential changes could translate into elevated IOP and glaucoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Uveoscleral outflow changes</measure>
    <time_frame>1-2 months</time_frame>
    <description>The uveoscleral outflow changes will be assess at baseline prior to any anti-VEGF treatment and after the 3rd intravitreal treatment has been done.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Macular Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with established diagnosis of retinal vascular diseases (diabetic macular edema,&#xD;
        neovascular macular degeneration, presumed ocular histoplasmosis syndrome, high myopia) who&#xD;
        require intravitreal injection of anti-VEGF drugs such as bevacizumab, ranibizumab or&#xD;
        aflibercept and are likely to need three monthly doses.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be at least 19 years of age and older&#xD;
&#xD;
          -  Ability to give informed consent and attend the study visits&#xD;
&#xD;
          -  Patients with established diagnosis of retinal vascular diseases (diabetic macular&#xD;
             edema, neovascular macular degeneration,presumed ocular histoplasmosis syndrome, high&#xD;
             myopia) who require intravitreal injection of anti-VEGF drugs such as&#xD;
             bevacizumab,ranibizumab or aflibercept and are likely to need three monthly doses.&#xD;
&#xD;
          -  Patients who have not received intravitreal injections within 3 months of study entry&#xD;
&#xD;
          -  No previous established diagnosis of glaucoma and consequently no previous history of&#xD;
             Argon Laser Trabeculoplasty (ALT) or Selective Laser Trabeculoplasty (SLT).&#xD;
&#xD;
          -  No previous history of ocular surgery&#xD;
&#xD;
          -  Patients who are not planning on and are unlikely to require an elective ocular&#xD;
             surgical or laser procedure within the study duration&#xD;
&#xD;
          -  Open angle of the anterior chamber on clinical examination&#xD;
&#xD;
          -  Ability to cooperate for aqueous humor dynamic studies&#xD;
&#xD;
          -  Contact lenses removed prior to topical fluorescein instillation, and not used until&#xD;
             the end of each fluorophotometry session&#xD;
&#xD;
          -  Able to participate on site over the multi-visit study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years of age&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  Ocular hypertension or glaucoma&#xD;
&#xD;
          -  Narrow angle with complete or partial closure (gonioscopy angle &lt;2)&#xD;
&#xD;
          -  Any previous surgical or laser procedures&#xD;
&#xD;
          -  Secondary glaucoma including pigmentary, exfoliative, uveitic and traumatic glaucomas&#xD;
&#xD;
          -  Any active neovascularization of the iris, angle, disc or retina&#xD;
&#xD;
          -  Diagnosis of retinal arterial or vein occlusion&#xD;
&#xD;
          -  Chronic or recurrent inflammatory eye disease&#xD;
&#xD;
          -  Ocular trauma within the past 6 months&#xD;
&#xD;
          -  Ocular infection or ocular inflammation in the past 2 months&#xD;
&#xD;
          -  Any abnormality preventing reliable fluorophotometry of either eye,such as corneal&#xD;
             scarring or severe dry eye that results in punctuate fluorescein staining of the&#xD;
             cornea&#xD;
&#xD;
          -  Intraocular surgery within 6 months&#xD;
&#xD;
          -  Serious hypersensitivity to any components of the study medications or risk from&#xD;
             treatment with glaucoma medications, such as severe asthma or emphysema.&#xD;
&#xD;
          -  Use of any glucocorticoid by any route. Subject must be washed out of the&#xD;
             glucocorticoid for at least 2 weeks before study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikas Gulati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNMC Department of Ophthalmology and Visual Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vikas Gulati, MD</last_name>
    <phone>402-559-4276</phone>
    <email>vgulati@unmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristi Miller</last_name>
    <phone>402-559-1853</phone>
    <email>kristi.miller@unmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Nebraska Medical Center, Truhlsen Eye Institute</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Gulati, MD</last_name>
      <phone>402-559-4276</phone>
      <email>vgulati@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristi Miller</last_name>
      <phone>402-559-1853</phone>
      <email>Kristi.miller@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shane Havens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kunal Dansingani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carol B Toris, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center, Department of Ophthalmology and Visual Sciences</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Gulati, MD</last_name>
      <phone>402-559-4276</phone>
      <email>vgulati@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristi Miller</last_name>
      <phone>402-559-1853</phone>
      <email>kristi.miller@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vikas Gulati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Vikas Gulati, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>vascular</keyword>
  <keyword>retina</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>Aqueous humor dynamics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

